Why an AI Enhanced Approach to Pharmacovigilance Case Processing is now Non-negotiable
Qinecsa CEO, Adam Sherlock has been featured in Simedics (The Journal of mHealth) discussing the critical role of AI-enhanced adverse event case processing in pharmacovigilance.
In this article, Adam highlights how technology-driven approaches are vital to ensuring the safety and effectiveness of breakthrough treatments – from weight-loss therapies to ongoing COVID-19 vaccine monitoring. Now more than ever, AI is a game-changer in optimizing patient safety and regulatory compliance.
